IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes

Novo NordiskTo mark World Heart Day today, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes. The global survey - Taking Diabetes to Heart - is available in multiple languages until March 2018, and people with type 2 diabetes are encouraged to participate.

Cardiovascular disease, which includes stroke, coronary heart disease and peripheral artery disease,(2) is one of the leading causes of death in people with type 2 diabetes,(1,3) and as the number of people with diabetes continues to increase,(4) the outlook for CVD becomes even more alarming.

"The world is facing rising prevalence and incidence of cardiovascular disease among people with type 2 diabetes, due to limited knowledge on prevention, poor access to timely diagnosis, inappropriate treatment and insufficiently informed self-management. Taking Diabetes to Heart is a global effort to tackle the underlying issues behind diabetes and cardiovascular diseases, their escalating costs to societies, and to support cost-effective interventions that can help reduce the current burden that they represent," said Dr Shaukat Sadikot, IDF president.

Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart/survey - aims to define the actions that are required to support knowledge and awareness of CVD among people living with type 2 diabetes to improve their health outcomes. It builds on the IDF global report Diabetes and Cardiovascular Disease, published in 2016, which includes a series of recommendations to reduce the burden of CVD among people with diabetes and the general population.(5)

"It is concerning that cardiovascular disease is the most common cause of death in people with type 2 diabetes when many of these patients are unaware of this risk," said Alan Moses, senior vice president and chief medical officer of Novo Nordisk. "We are delighted to support the IDF in launching the survey, Taking Diabetes to Heart, to better understand the current knowledge and awareness of cardiovascular disease among people with type 2 diabetes, which will ultimately inform actions needed to help improve health outcomes."

Taking Diabetes to Heart will culminate in a comprehensive report with country-specific results and resources to help support knowledge and awareness of CVD among people with type 2 diabetes around the world.

For more information about Taking Diabetes to Heart, visit www.idf.org/takingdiabetes2heart

For more information about diabetes and CVD, visit www.idf.org/cvd

About the International Diabetes Federation
The International Diabetes Federation (IDF) is an umbrella organisation of over 230 national diabetes associations in 165 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. The Federation's activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO).

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries.

About Taking Diabetes to Heart
Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart - consists of an online survey that will be available in multiple languages, including Arabic, Chinese, Danish, Japanese, English, French, Spanish, Russian, Hindi, Korean, Portuguese, German and Urdu. The survey will remain online until March 2018. Results from the survey will be used to inform policy and decision-making around this common and serious complication of diabetes.(4)

1. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009.
2. Danaei G, Lawes CM, Vander Hoorn S, et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. The Lancet. 2006; 368:1651-1659. DOI: 10.1016/s0140-6736(06)69700-6.
3. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014; 5: 444-470. DOI: 10.4239/wjd.v5.i4.444.
4. International Diabetes Federation. IDF Diabetes Atlas, 7th Edition. Brussels, Belgium: International Diabetes Federation, 2015. Available at: www.diabetesatlas.org. Last accessed: September 2017.
5. International Diabetes Federation. Diabetes and Cardiovascular Disease. Brussels, Belgium: International Diabetes Federation, 2016. Available at: www.idf.org/cvd. Last accessed: September 2017.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...